Aiding Mankind with CNS disorders by providing the Right Solution: ACADIA PHARMACEUTICALS

Committed to improving patients’ lives

ACADIA (NASDAQ: ACAD) shares a passion for improving the lives of patients with central nervous system (CNS) disorders. In April 2016, the company received FDA approval for NUPLAZID^® (pimavanserin), the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. In addition, ACADIA has ongoing clinical development efforts in additional areas with significant unmet need, including pimavanserin for dementia-related psychosis, schizophrenia inadequate response, schizophrenia negative symptoms, and major depressive disorder and trofinetide for Rett syndrome.

The vision of the company is to become the leading pharmaceutical company dedicated to the advancement of innovative medicines that improve the lives of patients with CNS disorders. Its history is rooted in science and strong leadership in CNS research. The firm has set itself apart by transforming its novel discoveries into important drugs and drug candidates that may make a meaningful impact on the lives of patients and the family members who care for them every day.

The Company’s Core Values

• ACADIA is driven to improve lives – it never loses sight of its patients and their families.
• “None of us is as smart as all of us,” says ACADIA – it believes all ideas and outcomes are improved through collaboration.
• Mutual respect, integrity, and trust are its foundation.
• The firm challenges conventional thinking.
• Overcoming barriers are core to its culture – “we never give up,” is the motto.
• Getting things done – excellence is the result of its focus, expertise, and
• The company really takes its work seriously.

The Product of the Company

NUPLAZID^® (pimavanserin) 34mg capsules:

NUPLAZID^® (pimavanserin) is the first and only medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). It has always invited its customers to visit its product website of NUPLAZID. In this website, it has always given the right details of the content and solution this medicine provide. Although there is a catch, the product information is for U.S. residents only.

In 2018, the FDA conducted a thorough evaluation of NUPLAZID, which concluded with a public statement on September 20, 2018, that reaffirmed the positive benefit/risk profile of NUPLAZID for patients with hallucinations and delusions associated with PDP.

ACADIA refers to all healthcare providers, patients, and families to review the full statement issued by the FDA on September 20, 2018,

In line with the FDA evaluation, there is no new safety update to NUPLAZID prescribing information. Key documents prepared during the Tracked Safety Issue (TSI) evaluation of NUPLAZID, which formed the basis of the FDA’s September 20, 2018, public statement.

What is Parkinson’s disease?

Parkinson's disease or PD for short is a long-term degenerative disorder of the central nervous system; it majorly affects the motor system of the body. When the disease becomes worst, non-motor symptoms eventually increases and affects the body even more. The symptoms usually come on gradually over time. Early stages of the symptoms show the shaking of the body, rigidity of the body, slow movement of the body, and the struggle with walking. Furthermore, thinking and behavioral problems can also happen. That is when dementia becomes common in the advanced stages of body disease. It is common to have depression and anxiety as well. This is said to occur in more than a third of people with PD. There will be sleepless nights, and emotional problems or break downs. The main motor symptoms are collectively called "parkinsonism", or a "parkinsonian syndrome".

The Leading Man

Stephen R. Davis | CEO

Davis joined ACADIA in July 2014 as Executive Vice President, Chief Financial Officer, and Chief Business Officer. He was appointed Interim Chief Executive Officer in March 2015 and President and Chief Executive Officer in September 2015. Mr. Davis brings over 20 years of executive-level experience in the pharmaceutical industry and more than 20 years of experience on the boards of directors of publicly held biopharmaceutical companies. Previously, Mr. Davis served as Executive Vice President and Chief Operating Officer at Heron Therapeutics, Inc., Executive Vice President, and Chief Operating Officer at Ardea Biosciences, Inc., and in numerous executive roles at Neurogen Corporation, including Chief Executive Officer. Mr. Davis currently serves on the Board of Directors of Bellicum Pharmaceuticals, Inc. He also recently served on the boards of directors of SynagevaBioPharma Corp., Heron Therapeutics, and Furiex Pharmaceuticals, Inc. Early in his career, Mr. Davis practiced as a Certified Public Accountant with a major accounting firm and as a corporate and securities attorney with a Wall Street law firm. Mr. Davis received his Bachelor of Science degree in Accounting from Southern Nazarene University and a J.D. from Vanderbilt University.

“ACADIA’s mission is to be the leading pharmaceutical company dedicated to the advancement of innovative medicines that improve the lives of patients with central nervous system disorders.”